Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific has demonstrated a robust performance with significant year-over-year sales growth across multiple product categories, including a 35% increase in Watchman sales and a remarkable 63% growth in electrophysiology (EP), indicating strong market demand and share gains. The company has provided favorable guidance for Q4, projecting organic sales growth between 11-13% and an adjusted EPS range of $0.48 to $0.52, reflecting positive trends in its coronary therapies and diagnostics franchises. Additionally, the promising outlook for the Nalu product, with anticipated sales exceeding $60 million in 2025 and a growth rate of over 25% in 2026, further supports a positive long-term financial outlook for Boston Scientific.

Bears say

Boston Scientific faces a negative outlook due to expected foreign exchange headwinds, anticipated to reduce adjusted earnings by approximately $0.04 for the full year. The company's reliance on mature markets for its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios exposes it to ongoing pricing pressures, thereby limiting revenue growth potential. Additionally, challenges in product development and integration of new acquisitions could further hinder Boston Scientific's ability to meet internal revenue expectations, negatively impacting overall business performance.

Boston Scientific (BSX) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 19 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.